• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Nicergoline, an ameliorator of cerebral circulation and metabolism, decreases the norepinephine transporter, which are known as intracellular targets of anidepressants.

Research Project

Project/Area Number 24700576
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeMulti-year Fund
Research Field Rehabilitation science/Welfare engineering
Research InstitutionUniversity of Occupational and Environmental Health, Japan

Principal Investigator

ITOH Hideaki  産業医科大学, 医学部, 助教 (30609201)

Project Period (FY) 2012-04-01 – 2015-03-31
Project Status Completed (Fiscal Year 2014)
Budget Amount *help
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywordsニセルゴリン / 脳循環代謝改善薬 / 意欲低下 / ノルエピネフリントランスポーター / 抗うつ薬 / セロトニントランスポーター / 脳卒中後うつ / 意欲低下(アパシー) / 抗うつ作用 / 培養細胞 / 強制水泳テスト / アパシー / 細胞 / マウス
Outline of Final Research Achievements

Nicergoline is an ergoline derivative used to treat various symptoms related to cerebrovascular disease. There have been some studies that may support a trial of nicergoline for post-stroke depression, but the exact mechanism of the action is unknown. The aim of this study was to examine the effects of nicergoline on the norepinephrine transporter and serotonin transporter (SET), which are known as intracellular targets of anidepressants.
Nicergoline decreased the [3H]norepinephrine uptake by SK-N-SH cells in a concentration-dependent manner (0.1-10 M). Nicergoline decreased the [3H]serotonin uptake by SET-transfected COS-7 cells in the concentration of 100 M. In the FST, combined treatment with imipramine and nicergoline reduced the immobility time more than the treatment with imipramine alone.
The present findings suggest that nicergoline may decrease neuronal monoamine uptake, which could be useful for the treatment of post-stroke depression.

Report

(4 results)
  • 2014 Annual Research Report   Final Research Report ( PDF )
  • 2013 Research-status Report
  • 2012 Research-status Report
  • Research Products

    (12 results)

All 2014 2013 2012

All Presentation (12 results)

  • [Presentation] Nicergoline and Cilostazol decreases the function of norepinephine transporter, which is known as cellular target of antidepressants2014

    • Author(s)
      伊藤英明
    • Organizer
      The 9th World stroke congress
    • Place of Presentation
      トルコ・イスタンブール(Halic Congress Center)
    • Year and Date
      2014-10-22 – 2014-10-25
    • Related Report
      2014 Annual Research Report
  • [Presentation] 抗うつ薬の標的蛋白であるノルエピネフリントランスポーターに対する脳循環代謝改善薬の効果2014

    • Author(s)
      伊藤英明
    • Organizer
      第51回日本リハビリテーション医学会
    • Place of Presentation
      名古屋国際会議場・名古屋市
    • Year and Date
      2014-06-05 – 2014-06-07
    • Related Report
      2014 Annual Research Report
  • [Presentation] Nicergoline, an ameliorator of cerebral circulation and metabolism, decreases the norepinephine transporter, which are known as intracellular targets of anidepressants.2014

    • Author(s)
      伊藤英明
    • Organizer
      The 23rd European Stroke conference
    • Place of Presentation
      フランス・ニース(Nice-Acrolpolis Palais des Congres)
    • Year and Date
      2014-05-06 – 2014-05-09
    • Related Report
      2014 Annual Research Report
  • [Presentation] Nicergoline, an ameliorator of cerebral circulation and metabolism, decreases the norepinephine transporter, which are known as intracellular targets of anidepressants.2014

    • Author(s)
      伊藤英明
    • Organizer
      The 23rd European Stroke conference
    • Place of Presentation
      フランス・ニース(Nice Acropolis Convention center)
    • Related Report
      2013 Research-status Report
  • [Presentation] 脳循環改善薬・ニセルゴリンによるノルエピネフリントランスポーター機能の抑制機序についての検討2013

    • Author(s)
      伊藤英明
    • Organizer
      第60回 日本リハビリテーション医学会
    • Place of Presentation
      東京(東京国際フォーラム)
    • Related Report
      2013 Research-status Report
  • [Presentation] ニセルゴリンによるノルエピネフリントランスポーター機能抑制に対する一酸化窒素合成酵素の関与についての検討2013

    • Author(s)
      伊藤英明
    • Organizer
      第13回 日本NO学会
    • Place of Presentation
      沖縄(沖縄県医師会館)
    • Related Report
      2013 Research-status Report
  • [Presentation] Nicergoline decreases the function of norepinephrine transporter2013

    • Author(s)
      伊藤英明
    • Organizer
      The 43rd annual meeting of the Society for Neuroscience
    • Place of Presentation
      サンディエゴ(Sandiego convention center)
    • Related Report
      2013 Research-status Report
  • [Presentation] 脳循環改善薬・ニセルゴリンはノルエピネフリントランスポーター機能を抑制する2013

    • Author(s)
      伊藤英明
    • Organizer
      第38回脳卒中学会総会
    • Place of Presentation
      グランドプリンスホテル新高輪 (東京)
    • Related Report
      2012 Research-status Report
  • [Presentation] 脳循環改善薬・ニセルゴリンによるノルエピネフリントランスポーター機能の抑制機序についての検討2013

    • Author(s)
      伊藤英明
    • Organizer
      第50回リハビリテーション医学会
    • Place of Presentation
      東京国際フォーラム (東京)
    • Related Report
      2012 Research-status Report
  • [Presentation] ニセルゴリンによるノルエピネフリントランスポーター機能抑制に対する一酸化窒素合成酵素の関与についての検討2013

    • Author(s)
      伊藤英明
    • Organizer
      第13回日本NO学会
    • Place of Presentation
      沖縄県医師会館 (那覇)
    • Related Report
      2012 Research-status Report
  • [Presentation] 脳循環代謝改善薬・ニセルゴリンがモノアミントランスポーターに及ぼす影響2012

    • Author(s)
      伊藤英明
    • Organizer
      第59回 日本リハビリテーション医学会
    • Place of Presentation
      福岡国際会議場・福岡サンパレス(福岡)
    • Related Report
      2012 Research-status Report
  • [Presentation] The effects of nicergoline, an ameliorator of cerebral circulation and metabolism, on the monoamine transporter2012

    • Author(s)
      伊藤英明
    • Organizer
      8th World stroke congress
    • Place of Presentation
      Ulysses Guimarães Convention Center (Brasilia, Brasil)
    • Related Report
      2012 Research-status Report

URL: 

Published: 2013-05-31   Modified: 2019-07-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi